Parametrica Management Ltd Cuts Stake in Eli Lilly and Company (NYSE:LLY)

Parametrica Management Ltd reduced its stake in Eli Lilly and Company (NYSE:LLY) by 64.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,800 shares of the company’s stock after selling 3,300 shares during the period. Eli Lilly and Company makes up 1.9% of Parametrica Management Ltd’s portfolio, making the stock its 16th biggest position. Parametrica Management Ltd’s holdings in Eli Lilly and Company were worth $1,595,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of LLY. Pinnacle Financial Partners Inc boosted its position in shares of Eli Lilly and Company by 0.8% during the third quarter. Pinnacle Financial Partners Inc now owns 35,961 shares of the company’s stock valued at $31,859,000 after buying an additional 275 shares during the last quarter. Hartline Investment Corp boosted its position in shares of Eli Lilly and Company by 33.9% during the third quarter. Hartline Investment Corp now owns 26,958 shares of the company’s stock valued at $23,883,000 after buying an additional 6,818 shares during the last quarter. Mengis Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 2.2% during the third quarter. Mengis Capital Management Inc. now owns 7,559 shares of the company’s stock valued at $6,697,000 after buying an additional 160 shares during the last quarter. Simmons Bank boosted its position in shares of Eli Lilly and Company by 1.5% during the third quarter. Simmons Bank now owns 8,409 shares of the company’s stock valued at $7,450,000 after buying an additional 121 shares during the last quarter. Finally, Haverford Trust Co boosted its position in shares of Eli Lilly and Company by 0.9% during the third quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock valued at $3,114,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Truist Financial increased their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Citigroup raised their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Price Performance

LLY traded up $1.09 on Wednesday, hitting $819.95. 584,304 shares of the company’s stock traded hands, compared to its average volume of 3,103,903. The company’s 50 day simple moving average is $891.02 and its 200-day simple moving average is $870.71. The firm has a market cap of $778.39 billion, a price-to-earnings ratio of 88.52, a P/E/G ratio of 3.15 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.